journals.plos.org /4 days ago

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and <i>in silico&lt...

by Matteo Italia, Silvia Bordel-Vozmediano, José García Otero, Gabriel F. Calvo, Víctor M. Pérez-García Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-...

Read source
qchron.com /1 week ago

Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in a...

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activa...

Read source
bioengineer.org /3 weeks ago

Stationary full-ring SPECT/CT outperforms dual-head cameras in head-to-head patient study

In a 30-patient crossover study, a stationary full-ring SPECT/CT system detected 20% more bone metastases and delivered up to 4.8-fold higher signal-to-noise ratios than a conventi...

Read source
bioengineer.org /4 weeks ago

Breast Cancer Drug Lapatinib Shows Modest Boost to Ultrasound Therapy in Prostate Cancer Cells

A laboratory study finds that the approved kinase inhibitor lapatinib can improve retention of a nanoparticle sonosensitizer in hypoxic prostate cancer cells by blocking the ABCG2...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.